Cassava Sciences (NASDAQ:SAVA – Get Free Report) announced its quarterly earnings results on Monday. The company reported ($0.57) EPS for the quarter, topping analysts’ consensus estimates of ($0.68) by $0.11, Zacks reports.
Cassava Sciences Stock Performance
NASDAQ SAVA opened at $2.68 on Wednesday. The business’s fifty day moving average is $2.54 and its 200 day moving average is $15.12. The company has a market capitalization of $128.93 million, a PE ratio of -1.94 and a beta of -0.95. Cassava Sciences has a fifty-two week low of $2.23 and a fifty-two week high of $42.20.
Wall Street Analyst Weigh In
Separately, HC Wainwright reaffirmed a “neutral” rating on shares of Cassava Sciences in a report on Tuesday.
About Cassava Sciences
Cassava Sciences, Inc, a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease.
Featured Stories
- Five stocks we like better than Cassava Sciences
- Why Understanding Call Option Volume is Essential to Successful Options Trading
- Okta’s Stock Reversal Gains Momentum—20% Upside Ahead
- Stock Ratings and Recommendations: Understanding Analyst Ratings
- Tariffs Won’t Stop These 3 Stocks From Rising
- What is the Hang Seng index?
- Missed the Hims & Hers Rally? Clover Health Could Be Next
Receive News & Ratings for Cassava Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cassava Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
